{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:02:28Z","timestamp":1780308148743,"version":"3.54.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110024","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:18:15Z","timestamp":1780305495000},"source":"Crossref","is-referenced-by-count":0,"title":["Reverse Left Ventricular Remodeling in a Patient With Concurrent Wild-Type Transthyretin Cardiac Amyloidosis and Heart Failure With Reduced Ejection Fraction: The Role of Conventional Heart Failure Therapy"],"prefix":"10.7759","author":[{"given":"Koji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments","volume":"47","author":"Fontana M","year":"2026","unstructured":"Fontana M, Aimo A, Emdin M, Porcari A, Solomon SD, Hawkins PN, Gillmore JD. Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Eur Heart J. 2026, 47:54-63. 10.1093\/eurheartj\/ehaf667","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"31","author":"Buxbaum JN","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, F\u00e4ndrich M, et al.. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024, 31:249-56. 10.1080\/13506129.2024.2405948","journal-title":"Amyloid"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez E","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025, 46:999-1013. 10.1093\/eurheartj\/ehae811","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.10.054","article-title":"Myocardial amyloid burden in transthyretin amyloidosis","volume":"87","author":"Sheikh A","year":"2026","unstructured":"Sheikh A, Achten A, Aimo A, et al.. Myocardial amyloid burden in transthyretin amyloidosis. J Am Coll Cardiol. 2026, 87:505-18. 10.1016\/j.jacc.2025.10.054","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2418965","article-title":"Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction","volume":"56","author":"Achten A","year":"2024","unstructured":"Achten A, Muller SA, Wijk SS, et al.. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med. 2024, 56:2418965. 10.1080\/07853890.2024.2418965","journal-title":"Ann Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112","article-title":"Changing treatment landscape in transthyretin cardiac amyloidosis","volume":"18","author":"Fontana M","year":"2025","unstructured":"Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing treatment landscape in transthyretin cardiac amyloidosis. Circ Heart Fail. 2025, 18:e012112. 10.1161\/CIRCHEARTFAILURE.124.012112","journal-title":"Circ Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/24748706.2021.1954275","article-title":"Left ventricular reverse remodeling in heart failure: remission to recovery","volume":"5","author":"Boulet J","year":"2021","unstructured":"Boulet J, Mehra MR. Left ventricular reverse remodeling in heart failure: remission to recovery. Struct Heart. 2021, 5:466-81. 10.1080\/24748706.2021.1954275","journal-title":"Struct Heart"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac223","article-title":"Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies","volume":"43","author":"Frantz S","year":"2022","unstructured":"Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022, 43:2549-61. 10.1093\/eurheartj\/ehac223","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai T","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, et al.. JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J. 2025, 89:1278-444. 10.1253\/circj.CJ-25-0002","journal-title":"Circ J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102890","article-title":"Early diagnosis of ATTR-CM using carpal tunnel biopsy examination: EDUCATE: a United Kingdom prospective multicenter study","volume":"14","author":"Razvi Y","year":"2026","unstructured":"Razvi Y, Gilbertson J, Heras-Palou C, et al.. Early diagnosis of ATTR-CM using carpal tunnel biopsy examination: EDUCATE: a United Kingdom prospective multicenter study. JACC Heart Fail. 2026, 14:102890. 10.1016\/j.jchf.2025.102890","journal-title":"JACC Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-24-0733","article-title":"Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretin amyloid cardiomyopathy","volume":"89","author":"Kuyama N","year":"2025","unstructured":"Kuyama N, Izumiya Y, Takashio S, et al.. Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretin amyloid cardiomyopathy. Circ J. 2025, 89:421-31. 10.1253\/circj.CJ-24-0733","journal-title":"Circ J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association","volume":"47","author":"Garcia-Pavia P","year":"2026","unstructured":"Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, et al.. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J. 2026, 47:22-36. 10.1093\/eurheartj\/ehaf710","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83283","article-title":"An unusual case of transthyretin cardiac amyloidosis presenting as heart failure with improved ejection fraction without left ventricular hypertrophy","volume":"17","author":"Kurisu S","year":"2025","unstructured":"Kurisu S, Fujiwara H. An unusual case of transthyretin cardiac amyloidosis presenting as heart failure with improved ejection fraction without left ventricular hypertrophy. Cureus. 2025, 17:e83283. 10.7759\/cureus.83283","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/11532320-000000000-00000","article-title":"Amiodarone: review of pulmonary effects and toxicity","volume":"33","author":"Papiris SA","year":"2010","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010, 33:539-58. 10.2165\/11532320-000000000-00000","journal-title":"Drug Saf"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2023.2235881","article-title":"Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis","volume":"31","author":"Takahashi K","year":"2024","unstructured":"Takahashi K, Hiratsuka Y, Iwamura T, et al.. Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis. Amyloid. 2024, 31:12-21. 10.1080\/13506129.2023.2235881","journal-title":"Amyloid"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche C","year":"2024","unstructured":"Nitsche C, Ioannou A, Patel RK, et al.. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024, 26:2008-12. 10.1002\/ejhf.3354","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-22-0032","article-title":"New conversion formula between B-type natriuretic peptide and N-terminal-pro-B-type natriuretic peptide\u2014analysis from a multicenter study","volume":"86","author":"Ishihara S","year":"2022","unstructured":"Ishihara S, Hiramitsu S, Kanaoka K, et al.. New conversion formula between B-type natriuretic peptide and N-terminal-pro-B-type natriuretic peptide\u2014analysis from a multicenter study. Circ J. 2022, 86:2010-8. 10.1253\/circj.CJ-22-0032","journal-title":"Circ J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou A","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, et al.. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023, 44:2893-907. 10.1093\/eurheartj\/ehad347","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2025.41","article-title":"Reverse remodelling, myocardial recovery and remission in heart failure with reduced ejection fraction: clinical implications and management strategies","volume":"11","author":"Furquim SR","year":"2025","unstructured":"Furquim SR, Lira MT, Belfort DS, et al.. Reverse remodelling, myocardial recovery and remission in heart failure with reduced ejection fraction: clinical implications and management strategies. Card Fail Rev. 2025, 11:e33. 10.15420\/cfr.2025.41","journal-title":"Card Fail Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf332","article-title":"Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation","volume":"46","author":"Shinzato K","year":"2025","unstructured":"Shinzato K, Takahashi Y, Yamaguchi T, et al.. Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. Eur Heart J. 2025, 46:3437-49. 10.1093\/eurheartj\/ehaf332","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.051","article-title":"Amiodarone in the aged","volume":"42","author":"Srinivasan M","year":"2019","unstructured":"Srinivasan M, Ahmad L, Bhindi R, Allahwala U. Amiodarone in the aged. Aust Prescr. 2019, 42:158-62. 10.18773\/austprescr.2019.051","journal-title":"Aust Prescr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis","volume":"55","author":"Karakasis P","year":"2025","unstructured":"Karakasis P, Theofilis P, Patoulias D, et al.. Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis. Eur J Clin Invest. 2025, 55:e14392. 10.1111\/eci.14392","journal-title":"Eur J Clin Invest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.70281","article-title":"Catheter ablation and device therapy in patients with transthyretin amyloid cardiomyopathy: a review of non-pharmacological therapy","volume":"42","author":"Kanazawa H","year":"2026","unstructured":"Kanazawa H, Hoshiyama T, Kaneko S, et al.. Catheter ablation and device therapy in patients with transthyretin amyloid cardiomyopathy: a review of non-pharmacological therapy. J Arrhythm. 2026, 42:e70281. 10.1002\/joa3.70281","journal-title":"J Arrhythm"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0138","article-title":"Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - digest version","volume":"81","author":"Aonuma K","year":"2017","unstructured":"Aonuma K, Shiga T, Atarashi H, et al.. Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - digest version. Circ J. 2017, 81:581-612. 10.1253\/circj.CJ-66-0138","journal-title":"Circ J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino S","year":"2020","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020, 6:351-61. 10.1016\/j.jacep.2020.01.004","journal-title":"JACC Clin Electrophysiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25444","article-title":"Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia syndrome as a clinical profile leading to the diagnosis of transthyretin amyloidosis: a report of two cases","volume":"14","author":"Takahashi K","year":"2022","unstructured":"Takahashi K, Sakaue T, Uemura S, Okura T, Ikeda S. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia syndrome as a clinical profile leading to the diagnosis of transthyretin amyloidosis: a report of two cases. Cureus. 2022, 14:e25444. 10.7759\/cureus.25444","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches S","year":"2022","unstructured":"Vilches S, Fontana M, Gonzalez-Lopez E, et al.. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022, 24:1387-96. 10.1002\/ejhf.2566","journal-title":"Eur J Heart Fail"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana M","year":"2025","unstructured":"Fontana M, Ioannou A, Cuddy S, et al.. The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response. JACC Cardiovasc Imaging. 2025, 18:478-99. 10.1016\/j.jcmg.2024.10.011","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491434-reverse-left-ventricular-remodeling-in-a-patient-with-concurrent-wild-type-transthyretin-cardiac-amyloidosis-and-heart-failure-with-reduced-ejection-fraction-the-role-of-conventional-heart-failure-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:18:17Z","timestamp":1780305497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491434-reverse-left-ventricular-remodeling-in-a-patient-with-concurrent-wild-type-transthyretin-cardiac-amyloidosis-and-heart-failure-with-reduced-ejection-fraction-the-role-of-conventional-heart-failure-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.110024","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}